Nordic Pharma AAP is pleased to announce that the Nordixate® Methotrexate Pre-filled Syringe has been issued market authorization by Instituto Nacional de Vigilancia de Medicamentos y Alimentos, or INVIMA, the Colombian National Food and Drug Surveillance Institute.
Nordixate® is indicated for sever and active rheumatoid arthritis in adult patients; juvenile idiopathic arthritis in polyarthritics and severe forms when the response to non-steroidal antiinflammatory drugs has been inadequate; severe and generalized vulgar psoriasis, especially of the plaque type; psoriatic arthritis in adult patients who are not responding to conventional therapy, immunosuppressive therapy alone, or more commonly, in combination with other agents.
Methotrexate has long been considered the international gold standard among disease modifying anti-rheumatic drugs used to manage arthritis and other rheumatic disorders.
With our local partner, Vitalis Laboratorio, we are working towards a launch early next year.
Thank you to everyone who has been involved in achieving this approval.
For more information, please contact Nordic Pharma AAP or Vitalis Laboratorio:
Nordic Pharma Inc.
402-21 St Clair Ave E,
Toronto, ON, Canada M4T 1L9
+1 877 230 4227 info@nordicpharma.ca
